| Bioactivity | KT185 is an orally-bioavailable, brain-penetrant and selective ABHD6 inhibitor, with an IC50 0.21 nM in Neuro2A cells[1]. | ||||||||||||
| Target | IC50: ABHD6 (0.21 nM in Neuro2A cells). | ||||||||||||
| Name | KT185 | ||||||||||||
| CAS | 1472640-86-0 | ||||||||||||
| Formula | C32H33N5O2 | ||||||||||||
| Molar Mass | 519.64 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hsu KL, et al. Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (ABHD6). J Med Chem. 2013 Nov 14;56(21):8270-9. |